Mr. Michael Halstead reports

HELUS PHARMA APPOINTS REGINA DONOHUE AS CHIEF PEOPLE OFFICER AND SURESH DURGAM, M.D., TO ITS SCIENTIFIC ADVISORY BOARD

Helus Pharma (Cybin Inc.) has appointed Regina Donohue as chief people officer and has appointed Suresh Durgam, MD, to the company's scientific advisory board.

"I had the pleasure of working with both Regina and Suresh at Intra-Cellular, and I am delighted to welcome them to Helus Pharma," said Michael Halstead, chief executive officer of Helus Pharma. "As we execute against our upcoming clinical, regulatory and commercial milestones, Regina's experience thoughtfully scaling organizations and building high performing teams will be instrumental. Suresh's deep expertise in CNS clinical development, regulatory strategy and scientific leadership will further strengthen our SAB as we advance our pipeline toward potential commercialization."

Chief people officer appointment

Ms. Donohue has extensive human resource leadership experience working with life science companies amidst their transition from clinical platforms through commercialization by building scalable human resources functions through periods of rapid growth.

Most recently, at Intra-Cellular, Ms. Donohue served as chief human resources officer, where she built the company's people strategy and infrastructure, and managed its rapid growth as it transitioned into a commercial-stage organization, launched its first product and grew to 1,000-plus employees. Intra-Cellular was acquired by Johnson & Johnson in April, 2025.

Previously, Ms. Donohue was among the first five executives hired to build LEO Pharma's U.S. subsidiary, establishing its human resource function and supporting the organization through the rapid growth necessary to launch two products in the U.S. During her tenure at LEO Pharma, she also served as the interim global head of human resources.

"I am thrilled to join a company so deeply committed to advancing innovative treatments for people living with mental health conditions," said Ms. Donohue. "Mental health is a cause that is personally meaningful to me, and I am particularly excited to bring my experience and passion for building strong, purpose-driven organizations to Helus Pharma. The company is at an exciting stage of its growth, and I look forward to helping build a patient-centric culture and developing the strong people strategy Helus Pharma will need as it advances towards potential commercialization of its programs."

Ms. Donohue holds a bachelor of science from the University of Scranton and professional human resource designations from the HR Certification Institute and Society for Human Resources Management.

SAB appointment

Dr. Durgam is a CNS drug development executive with more than two decades of experience spanning clinical development, medical affairs, regulatory strategy and pharmacovigilance. Most recently, he served as executive vice-president and chief medical officer of Intra-Cellular, where he provided strategic oversight across global clinical development and operations, data science, regulatory affairs, drug safety, and medical affairs. He played a pivotal role in securing FDA approvals for CAPLYTA across multiple indications, including schizophrenia, bipolar depression, as both a monotherapy and adjunctive therapy, and adjunctive major depressive disorder.

Earlier in his career, Dr. Durgam held senior clinical development leadership roles at Allergan, Forest Laboratories and Solvay Pharmaceuticals, with responsibility for programs across major depressive disorder, bipolar disorder, schizophrenia and anxiety disorders. His development experience includes lumateperone, cariprazine, vilazodone, levomilnacipran and other CNS therapies. He has led or supported numerous interactions with regulatory authorities worldwide and written or co-written more than 50 peer-reviewed publications and over 200 abstracts and posters.

"Helus Pharma is advancing a differentiated CNS pipeline with the potential to address significant unmet needs in mental health," said Dr. Durgam. "I look forward to working with the company's leadership team and fellow SAB members to provide scientific and clinical guidance as Helus Pharma advances its programs through late-stage development."

Dr. Durgam received his psychiatry residency training at Scott & White Memorial Hospital within the Texas A&M University System College of Medicine and earned his medical degree from Siddhartha Medical College in India. He is a member of the scientific committee of the International Society for CNS Clinical Trials and Methodology, and received the 2026 International Society for CNS drug development leadership award.

About Helus Pharma

Helus Pharma, the commercial operating name of Cybin, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of MDD that has received breakthrough therapy designation from the Food and Drug Administration, and HLP004, also a proprietary NSA in phase 2 for GAD. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

We seek Safe Harbor.